2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Epilepsy

Epilepsy

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures due to abnormal electrical activity in the brain, with symptoms ranging from brief lapses in awareness to convulsions. It is typically diagnosed after two or more seizures occurring more than 24 hours apart, or after a single seizure with high recurrence risk. Causes include genetic factors, brain injury, infections, tumors, stroke, developmental disorders, and metabolic or structural abnormalities. The SCN1A gene is notably associated with epilepsy, particularly in syndromes like Dravet syndrome and juvenile myoclonic epilepsy, with related pathways involving neuroscience and neuropathic pain signaling. Treatment includes anti-seizure medications, lifestyle modifications, and surgical options, though about 30% of patients continue to experience seizures despite therapy. Epilepsy can affect individuals of any age, with involvement of brain regions such as the temporal lobe and phenotypes related to nervous system dysfunction and growth abnormalities. Associated conditions include post-traumatic epilepsy, childhood absence epilepsy, and myoclonic epilepsy, with triggers including trauma, CNS infections, and degenerative brain disorders. Zinc cation and selenium have been explored in the context of management.

References:

Epilepsy (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2912
    Glutamate dehydrogenase (NADP) 9029-11-2
    Glutamate dehydrogenase (NADP) is the catalytic enzyme for glutamate production. Dysfunction of Glutamate dehydrogenase (NADP) may induce various neurodegenerative diseases, such as Parkinson's disease, epilepsy, Alzheimer's disease, schizophrenia, and frontotemporal dementia. Glutamate dehydrogenase (NADP) can be used in research on neurological diseases such as Parkinson's disease, epilepsy, and Alzheimer's disease.
    Glutamate dehydrogenase (NADP)
  • HY-D2968
    DCM–ONOO 2759816-87-8
    DCM-ONOO is a near-infrared two-photon fluorescence probe specifically designed for real-time monitoring of the dynamic fluctuations of peroxynitrite (ONOO⁻) in epilepsy models. DCM-ONOO exhibits excellent optical properties, with a single photon excitation (Ex) of 520 nm; a single photon emission (Em) of 685 nm; a two-photon excitation of 820 nm; and a Stokes shift of 165 nm. When DCM-ONOO is combined with ONOO⁻, it shifts from 460 nm to 512 nm, and only generates a significant fluorescence response to ONOO⁻. DCM-ONOO has been successfully applied to rat epilepsy models.
    DCM–ONOO